miR‑150 is a negative independent prognostic biomarker for primary gastrointestinal diffuse large B‑cell lymphoma

Abstract

A number of studies suggest an association between miRNAs and diffuse large B-cell lymphoma (DLBCL). The present study aimed to investigate the prognostic value of microRNA (miR-150) in primary gastrointestinal (PGI)-DLBCL, by assessing the association between miR-150 expression and clinicopathological characteristics in patients with PGI-DLBCL. A total of 84 patients diagnosed with PGI-DLBCL were recruited and both tumor and adjacent non-tumor tissue samples were collected. miR-150 expression was assessed via reverse transcription-quantitative (RT-q)PCR analysis. The results demonstrated that miR-150 expression was significantly lower in PGI-DLBCL tissues compared with adjacent non-tumor tissues. Furthermore, receiver operating characteristic (ROC) curve analysis indicated that the optimal cut-off value of miR-150 for predicting survival was 8.965 with high sensitivity (79.8%) and specificity (77.1%). Patients were divided into two groups according to this cut-off value, as follows: High (n=18) and low expression (n=66) groups. Low miR-150 expression was significantly associated with clinical stage, International Prognostic Index (IPI), Eastern Cooperative Oncology Group status and use of rituximab. RT-qPCR analysis demonstrated that miR-150 expression was significantly lower in patients with high IPI scores compared with patients with low IPI scores. Downregulated miR-150 expression was significantly associated with shorter overall survival (OS) time and progression-free survival (PFS) time in patients with PGI-DLBCL. Furthermore, miR-150 level and IPI score were identified as two risk factors for OS and PFS. The diagnostic value of miR-150 was evaluated via ROC curve analysis, with an area under the curve value of 0.882. Taken together, the results of the present study suggest that miR-150 is a potential diagnostic marker of PGI-DLBCL, and may also serve as a useful prognostic factor for survival outcomes in patients with PGI-DLBCL.

Multiple functions and regulatory network of miR-150 in B lymphocyte-related diseases

“…Recently, miR-150 started to receive increasing attention due to its tumor suppressive role in hematological malignancies ( 53 ). MIR-150 is downregulated in several B-lymphocyte malignancies ( 49 , 54 – 57 ), such as diffuse large B-cell lymphoma (DLBCL) ( 55 ), mantle cell lymphoma (MCL) ( 54 ), BL ( 9 ) and aggressive chronic lymphocytic leukemia (CLL) ( 11 ). Besides, the MIR-150 is highly expressed in lymphocyte-derived exosomes and is easily detectable and significantly enriched in exosomes circulating in human blood ( 58 ).…”

“…Compared with memory B cells, miR-150 is much lower in other peripheral B-cell subpopulations, such as naïve B cells and centroblasts in DLBCL patients ( 55 ). Low MIR-150 expression is associated with poor clinical outcome predictions in patients with primary gastrointestinal DLBCL ( 57 ). Reduced miR-150 causes FOXP1 upregulation, promoting the growth and survival of B cells in DLBCL by enhancing BCR and NF-κB signaling ( 62 – 65 ).…”

The Role of microRNAs in the Infection by T. gondii in Humans

“…Several studies have related the use of microRNAs as new biomarkers in several diseases such as cancer (Wang et al, 2020;Kooshkaki et al, 2020;Di et al, 2020), cardiovascular (Sun et al, 2020), and bacterial diseases (Jia et al, 2014), as well as a noninvasive diagnosis and monitoring method of parasitic disease progression (Hu et al, 2013). A study by Jia et al, 2014 used 60 BALB/c female mice intraperitoneally infected with 10 6 tachyzoites of RH or ME49 strain per mice to assess the feasibility of using microRNAs as biomarkers of early T. gondii infection.…”

ceRNA Network of lncRNA/miRNA as Circulating Prognostic Biomarkers in Non-Hodgkin Lymphomas: Bioinformatic Analysis and Assessment of Their Prognostic Value in an NHL Cohort

“…It is clear that miRNAs and lncRNAs have a synergetic role in an intricated method to fine-tune gene expression; however additional studies are needed to further define the role of ncRNAs in clinical practice as potential new predictive and prognostic biomarkers. Hsa-miR-150-5p has been described as one of the players involved in B cell differentiation and as a potential non-invasive B cell lymphoma biomarker [ 22 , 23 ]. On the other hand, numerous studies showed that hsa-miR-335-5p is dysregulated in several cancers, such as breast cancer, lung cancer, colorectal cancer, and ovarian cancer [ 24 , 25 , 26 , 27 ].…”